Game-changing pan-TEAD inhibitor for solid tumours
Drug Target Review
JUNE 12, 2023
Leveraging AI-guided structure-based drug design, Insilico’s research and development team generated an impressive portfolio of over 6,000 molecules and identified three highly promising hit series. The novel molecules were further ranked based on their ADME and selectivity profiles.
Let's personalize your content